Evolent Health, Inc.
For the period ended Jun 30, 2026. Filed Aug 6, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On May 22, 2026, Seth Blackley, the Company’s Chief Executive Officer and a member of the Company’s Board of Directors, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “Blackley Plan”). The first possible trade date under the Blackley Plan is December 15, 2026, and the end date of the Blackley Plan is February 1, 2027. The aggregate amount of securities that may be sold under the Blackley Plan is 298,129 shares.
On May 22, 2026, Daniel McCarthy, the Company’s President, adopted a new trading plan for the sale of securities that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) of the Securities Exchange Act of 1934 (the “McCarthy Plan”). The first possible trade date under the McCarthy Plan is August 21, 2026, and the end date of the McCarthy Plan is February 19, 2027. The aggregate amount of securities that may be sold under the McCarthy Plan is 201,320 shares.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.